Seeking Alpha

Idera up big premarket

  • Shares of Idera Pharaceuticals (IDRA) are up 20% before the open on heavy volume in response to the firm's report of positive phase 2 clinical trial results for it psoriasis drug IMO-8400.
  • The 32-patient study met its primary endpoint of safety and tolerability over a 12-week period. No adverse events, dose reductions or discontinuations occurred.
  • The study also met its secondary endpoint of demonstrating clinical activity as assessed by Psoriasis Area and Severity Index (PASI) scores.
  • IMO-8400 has demonstrated activity in other autoimmune diseases such as lupus and arthritis.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs